Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified - PubMed (original) (raw)

Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified

Sarah Djebara et al. Viruses. 2019.

Abstract

There is a growing interest in phage therapy as a complementary tool against antimicrobial resistant infections. Since 2007, phages have been used sporadically to treat bacterial infections in well-defined cases in the Queen Astrid military hospital (QAMH) in Brussels, Belgium. In the last two years, external requests for phage therapy have increased significantly. From April 2013 to April 2018, 260 phage therapy requests were addressed to the QAMH. Of these 260 requests, only 15 patients received phage therapy. In this paper, we analyze the phage therapy requests and outcomes in order to improve upon the overall capacity for phage therapy at the QAMH.

Keywords: Belgium; Brussels; Escherichia coli; Pseudomonas aeruginosa; Staphylococcus aureus; antibiotic resistance; bacteriophages; phage therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Patient care workflow in phage therapy at the Queen Astrid military hospital in Brussels (Belgium). PT, phage therapy; QAMH, Queen Astrid military hospital.

Figure 2

Initiators of the 260 phage therapy requests.

Figure 3

Relative prevalence of 311 reported bacterial pathogens (Table 1).

Figure 4

The proportion of the three most prevalent bacteria in the different infection types. AbdI, abdominal infection; BoneI, bone infection; ENT, ear-nose-throat; LRTI, lower respiratory tract infection; OPI, Orthopedic prosthesis infection; SSTI, skin and soft tissue infection; UTI, urinary tract infection.

Figure 5

Proportion of drug-resistant strains in the three most prevalent bacterial pathogens (see also Supplementary Table S1). MDR, multidrug-resistant; non-MDROs, non-multidrug-resistant organisms; Pan DR, pandrug-resistant; XDR, extensively drug-resistant.

Cited by

"French Phage Network" Annual Conference 2018-Fourth Meeting Report.
Froissart R, Brives C, Breyton C, Le Marrec C. Froissart R, et al. Viruses. 2019 May 23;11(5):470. doi: 10.3390/v11050470. Viruses. 2019. PMID: 31126089 Free PMC article.
Managing Patient and Clinician Expectations of Phage Therapy in the United Kingdom.
Jones JD, Stacey HJ, Brailey A, Suleman M, Langley RJ. Jones JD, et al. Antibiotics (Basel). 2023 Mar 2;12(3):502. doi: 10.3390/antibiotics12030502. Antibiotics (Basel). 2023. PMID: 36978369 Free PMC article.
Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.
Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, Wagemans J, Lood C, Schrevens E, Chanishvili N, Kutateladze M, de Jode M, Ceyssens PJ, Draye JP, Verbeken G, De Vos D, Rose T, Onsea J, Van Nieuwenhuyse B; Bacteriophage Therapy Providers; Bacteriophage Donors; Soentjens P, Lavigne R, Merabishvili M. Pirnay JP, et al. Nat Microbiol. 2024 Jun;9(6):1434-1453. doi: 10.1038/s41564-024-01705-x. Epub 2024 Jun 4. Nat Microbiol. 2024. PMID: 38834776 Free PMC article.
Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection.
Ferry T, Kolenda C, Laurent F, Leboucher G, Merabischvilli M, Djebara S, Gustave CA, Perpoint T, Barrey C, Pirnay JP, Resch G. Ferry T, et al. Nat Commun. 2022 Jul 22;13(1):4239. doi: 10.1038/s41467-022-31837-9. Nat Commun. 2022. PMID: 35869081 Free PMC article.
Compassionate Use of Bacteriophages for Failed Persistent Infections During the First 5 Years of the Israeli Phage Therapy Center.
Onallah H, Hazan R, Nir-Paz R; Israeli Phage Therapy Center (IPTC) Study Team. Onallah H, et al. Open Forum Infect Dis. 2023 Apr 20;10(5):ofad221. doi: 10.1093/ofid/ofad221. eCollection 2023 May. Open Forum Infect Dis. 2023. PMID: 37234511 Free PMC article.

References

1. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance. [(accessed on 10 February 2019)]; 2016 Release. Available online: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20c....
1. United Nations Draft political declaration of the high-level meeting of the General Assembly on antimicrobial resistance (16-16108 (E)) [(accessed on 10 February 2019)]; 2016 Release. Available online: https://www.un.org/pga/71/wp-content/uploads/sites/40/2016/09/DGACM_GAEA....
1. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. [(accessed on 10 February 2019)]; Available online: https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-ba....
1. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 2009;197:1079–1081. doi: 10.1086/533452. - DOI - PubMed
1. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009;48:1–12. doi: 10.1086/595011. - DOI - PubMed

Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified - PubMed (original) (raw)